Immune System

Category

Immune Disorder Biotech Plans IPO

Read Sarah de Crescenzo of Xconomy as she reports that La Jolla, CA-based Equillium, founded in 2017 as Attenuate Biopharmaceuticals, licensed its antibody drug candidate itolizumab (which it calls EQ001) from Biocon Limited (NSE: BIOCON), India’s largest...

Pin It on Pinterest